Loading stock…

Medline Inc. (MDLN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Medline Inc.

MDLNMarket cap $31BPrice $35.5

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Manufactures and distributes medical supplies, from gloves to surgical kits, that hospitals and clinics depend on daily. Privately held and family-run for decades, it quietly outfits more U.S. healthcare facilities than almost any name you've actually heard of.

In Bastion Portfolios?

52W Return-8%

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+10%7

Revenue Forecast

Rev CAGR (1y)+10%6

Rev CAGR (3y)+8%6

Rev CAGR (5y)+8%7

Earnings Forecast

EPS Growth Y+1+66%10

EPS Growth Y+2+2%4

EPS Growth Y+3+14%7

Quality

Margins

EBIT Margin5%3

Net Income Margin2%3

Free Cash Flow Margin5%4

Debt

Net Debt/EBITDA3.72

Efficiency

ROE5%3

ROA2%4

Earnings Stability1010

GEAR+WEAK25

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)156

P/E Ratio (Forward 3y)136

P/BV4.04

EV Multiples

EV/EBITDA Fwd144

EV/EBIT Fwd165

Yield

Free Cash Flow Yield3.3%5

Dividend Yieldna–

Momentum

Short term

1 month return+2%9

3 month return-12%3

YTD return-16%3

Mid term

Price vs 52wHigh70%3

1 year return-14%3

Long term

3 year return-14%2

5 year return-14%3

Risk Shield

Price Risk

Betana–

Volatility46%4

Free Cash Flow

Free Cash Flow Margin5%4

Free Cash Flow Yield3.3%5

Quality

ROCE4%3

Earnings Stability1010

Net Debt/EBITDA3.72

02Growth

Is it actually growing, and how fast?

MDLNMedline

Revenue FY25$28.4B

GROWTH RATING↗

AVERAGE62 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+66%10

EPS growth, FY27E+2%4

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 8%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 62% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 10%/yr over the last 3 years and is set to keep growing around 8%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%9

3-month return-12%3

YTD return-16%3

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return-14%3

3-year return-14%2

5-year return-14%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+2%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-14% over three years and -14% over five), behind 70% of the market.

It's down 14% over the past year, now 30% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-12%) and so far this year (-16%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Medline Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MDLNMedline

Revenue FY25$28.4B

GROWTH RATING↗

AVERAGE62 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+66%10

EPS growth, FY27E+2%4

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 8%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 62% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 10%/yr over the last 3 years and is set to keep growing around 8%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%9

3-month return-12%3

YTD return-16%3

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return-14%3

3-year return-14%2

5-year return-14%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+2%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-14% over three years and -14% over five), behind 70% of the market.

It's down 14% over the past year, now 30% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-12%) and so far this year (-16%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Medline Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community